Navigation Links
OPPI Opposes Draft National Pharmaceuticals Policy

Coming down heavily on the draft National Pharmaceuticals Policy, industry body OPPI has said the proposed policy will hamper the growth of the pharmaceutical sector // and lead to the destruction of Indian pharma companies.

"The previous governments had reduced the number of drugs under control from 347 to 143 and finally to 74. The Drug Policy in February 2002 had proposed a further reduction from 74 to about 30. The current policy hence will not promote the industry but would hamper its growth," Director General of Organisation of Pharmaceutical Producers of India Ajit V Dangi told PTI.

"The move (of bringing more drugs under price control) will act as a barrier to our growing markets and it will lead to the destruction of Indian Pharma companies," he said.

Instead of widening the list of drugs under the price control regime, the government should ensure access to basic healthcare facilities, Dangi added.

Criticising the proposal to include 354 drugs in the price control regime, he said it would drastically hit the margins of drug manufacturers.

He said the prices of medicines were already lowest in India, even lower than other neighbouring countries like Bangladesh, Sri lanka and Indonesia and there were no apparent reasons to reduce them further.

If the government wanted to lower it further then it should be looking at drugs taxation, he observed. The easier way to reduce prices is to cut taxes such as excise duty which push the prices of medicines up by 75 percent.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. HIV Patients Opposes Patenting Of AIDS Drug
2. Goa Christian Council Opposes Mandatory HIV Test
3. Smoking Ban Draft Is Put For Consultation
4. Kerala Drafts a New Health Tourism Policy
5. National Lung Study in the process
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. Hepatitis B Vaccine To Be Included In National Immunization Programme
8. UK Govt Says On Course For National Chlamydia Screening
9. Mexico and US border attain a new outlook due to BiNational Sustainability Laboratory
10. India extends National TB Control Program
11. President and Founder of National Obesity Forum Resigns
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... ... in the Garden of Eden”: retells the stories of three Bible figures in modern terms. ... Penelope Colt, mother, trader, horse farmer, artist and a former GM journeyman. Born in ... six, they moved to Dayton, Ohio, where Penny graduated high school. At sixteen, she ...
(Date:5/24/2017)... ... 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified ... is known for his distinguished expertise and experience in the diagnosis and treatment of ... in treating renovascular disease and aortic aneurysm . He is known for his ...
(Date:5/24/2017)... Cortland, OH (PRWEB) , ... May 24, 2017 , ... ... in Cortland, OH, can now meet with Dr. Joseph Bedich for a consultation, ... smiles while simultaneously improving their oral health and functionality. , Dr. Bedich ...
(Date:5/24/2017)... ... May 24, 2017 , ... Medic CE , a ... Truth about Pediatric Septic Shock” hosted by the Journal of Emergency Medical Services (JEMS). ... Eastern time, will be presented by Captain Rommie Duckworth, LP, a career fire captain ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... prominent for-profit and nonprofit hospitals and health systems in the nation and help ... their institutions, led professional organizations and been instrumental in developing successful hospital and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... Fla. , May 22, 2017  As ... as a whole continue to make the revolutionary ... becomes increasingly important for ensuring positive patient outcomes ... industry stakeholders are shifting focus away from clinical ... and effects of long-term specialty drug therapy utilization ...
(Date:5/18/2017)... N.J. , May 17, 2017  Bayer announced ... oncology portfolio will be presented at the 53 rd ... Oncology (ASCO), taking place June 2-6 in ... presented at ASCO span prostate, colorectal, liver and thyroid ... analysis from the Phase II CHRONOS-1 trial of copanlisib ...
(Date:5/15/2017)... Enterin Inc., a privately-held CNS pharmaceutical company based in ... Parkinson,s disease (PD), has enrolled the first patient in the ... multicenter study involving patients with PD and taking place at ... 9-to-12-month period. The first stage is open label and involves ... include Denver , Boca Raton ...
Breaking Medicine Technology: